Side-by-side · Research reference
HGH 191AAvsMOTS-c
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedHUMAN-REVIEWED0/75 cited
BAnimal-StrongHUMAN-REVIEWED16/68 cited
HGH 191AA
Recombinant hGH · FDA-Approved
0.024–0.034 mg/kg/dayPediatric GHD dose
2–4 hoursPlasma half-life
191 AASequence length
SQ · Daily · Evening preferred
MOTS-c
Mitokine · Mitochondria-Encoded
SQ · Variable · 2–3×/week
01Mechanism of Action
Parameter
HGH 191AA
MOTS-c
Primary target
Growth hormone receptor (GHR) — JAK2/STAT5 pathway
Mitochondrial 12S rRNA sORF → folate-AICAR-AMPK axisLee 2015
Pathway
GHR activation → JAK2/STAT5 → liver IGF-1 synthesis + direct metabolic effects
Downstream effect
Linear growth, lipolysis, protein synthesis, nitrogen retention, carbohydrate metabolism modulation
Enhanced fatty acid oxidation, GLUT4-mediated glucose uptake, mitochondrial bioenergetics, anti-inflammationLee 2015
Feedback intact?
No — exogenous GH bypasses hypothalamic-pituitary axis, suppresses endogenous pulsatility
Stress-responsive, AMPK-dependent nuclear translocationKim 2018
Origin
Recombinant DNA technology — 191 AA, identical to pituitary hGH, no methionyl residue
Endogenous 16-AA mitokine; mtDNA-encoded; declines with age; upregulated by exerciseReynolds 2021
Antibody development
Rare — <2% develop binding antibodies, typically non-neutralizing
—
02Dosage Protocols
Parameter
HGH 191AA
MOTS-c
Pediatric GHD
0.024–0.034 mg/kg/day SQ
6–7× per week dosing typical. Brand-specific ranges.
—
Adult GHD
0.004–0.016 mg/kg/day SQ
Start low, titrate based on IGF-1 levels.
—
Turner syndrome
0.045–0.050 mg/kg/day SQ
—
Idiopathic short stature
0.037 mg/kg/day SQ
—
AIDS wasting
0.1 mg/kg/day SQ (high-dose)
Short-term indication. Monitor glucose.
—
Frequency
Once daily, typically evening
Evening administration mimics physiological GH pulse.
2–3× per week
Short half-life may necessitate more frequent dosing for saturation.
Evidence basis
FDA-approved / decades of RCT data
Animal + anecdotalLee 2015Reynolds 2021A first-in-human phase 1 study 2021
Phase 1a/1b CB4211 analog trial completed 2021; no native MOTS-c RCT published.
Monitoring
IGF-1, glucose, thyroid function, bone age (children)
—
Duration
Years (children until epiphyseal closure); indefinite (adult GHD)
4–12 weeks (experimental)
Optimal cycle length unknown.
Standard dose
—
5–10 mg / weekLee 2015
Experimental, extrapolated from animal data. No human RCT-derived dose.
Lower / starter dose
—
2.5–5 mg / week
Recommended due to limited human data.
Reconstitution
—
Bacteriostatic water, 1–2 mL
10 mg/mL at 1 mL.
Timing
—
Pre-workout or fasted state preferred
Activity-context amplifies AMPK response.
Half-life
—
Minutes to hours (estimated)
Systemically unstable; native MOTS-c PK in humans not fully characterised.
03Metabolic / Fat Loss Evidence
Parameter
HGH 191AA
MOTS-c
Primary fat target
Visceral and subcutaneous adipose tissue
Diet-induced / metabolic obesity; systemic fat utilization
Mechanism
Lipolysis via hormone-sensitive lipase activation, FFA oxidation
—
Effect on lean mass
Significant lean mass increase (protein synthesis, nitrogen retention)
High dose significantly ↑ lean mass in mice
Insulin sensitivity
Acute insulin resistance (anti-insulin effect); chronic neutral-to-improved via fat loss
Reversed HFD insulin resistance in 7 days (mice)Lee 2015
IGF-1 elevation
Dose-dependent, significant — primary anabolic mediator
—
Glucose metabolism
Hyperglycemia risk, especially high doses (AIDS wasting)
Improved glucose tolerance; GLUT4 upregulationLee 2015
Body composition
↓ fat mass, ↑ lean mass, ↑ bone mineral density (children)
—
Clinical context
FDA-approved for AIDS wasting (cachexia). Off-label use for body recomposition lacks long-term safety data.
—
Quantified reduction
—
Significant HFD fat gain ↓Lee 2015
Murine models, dose-dependent (5 & 15 mg/kg).
IGF-1 impact
—
No direct IGF-1 pathway; AMPK-mediated
Triglycerides
—
AMPK-driven FA oxidation suggests TG benefit (not directly measured)
Effect reversibility
—
Unknown — no long-term follow-up data
Key publication
—
Lee Cell Metab 2015 · Reynolds Nat Commun 2021 · Kim Cell Metab 2018Lee 2015Reynolds 2021Kim 2018
04Side Effects & Safety
Parameter
HGH 191AA
MOTS-c
Injection site reaction
Lipohypertrophy, lipoatrophy, erythema (rotate sites)
Mild irritation (reported)
Fluid retention / Edema
Peripheral edema, arthralgia, carpal tunnel syndrome (dose-dependent)
Not reported
Glucose intolerance
Hyperglycemia, new-onset diabetes (anti-insulin effect)
Improves glucose toleranceLee 2015
Intracranial hypertension
Benign intracranial hypertension (pseudotumor cerebri) — headache, visual changes, papilledema
—
Slipped capital femoral epiphysis
SCFE risk in children — limp, hip/knee pain (requires surgery)
—
Scoliosis progression
Rapid growth may unmask/progress scoliosis (monitor spine in children)
—
Hypothyroidism
Central hypothyroidism unmasking or worsening (monitor TSH, free T4)
—
Cancer risk
Contraindicated in active malignancy. Theoretical risk in cancer survivors (controversial).
Contradictory data — some models suggest pro-proliferative effects
Antibody formation
Rare (<2%), typically non-neutralizing. Loss of efficacy if neutralizing antibodies develop.
No data (no long-term human trials)
Pancreatitis
Rare. Higher risk in children with certain syndromes (Prader-Willi).
—
Gynecomastia
Adolescent males (physiological during puberty, may be exacerbated)
—
Cardiovascular
—
Heart palpitations (anecdotal); cardiac hypertrophy reversed in diabetic rats
CNS / Neurological
—
Insomnia, headache (anecdotal reports)
GI symptoms
—
Nausea, stomach discomfort (reported)
Pregnancy / OB
—
Avoid — insufficient safety data
Evidence quality
—
Phase 1 analog (CB4211); preclinical; anecdotal humanA first-in-human phase 1 study 2021
Absolute Contraindications
HGH 191AA
- ·Active malignancy or history of cancer (especially childhood cancer survivors with risk factors)
- ·Acute critical illness (post-cardiac surgery, trauma, acute respiratory failure)
- ·Diabetic retinopathy (active proliferative or severe non-proliferative)
- ·Prader-Willi syndrome with severe obesity, sleep apnea, or respiratory impairment
- ·Closed epiphyses (for growth indications)
MOTS-c
- ·Pregnancy / breastfeeding (insufficient data)
Relative Contraindications
HGH 191AA
- ·Diabetes mellitus (monitor closely, may require insulin adjustment)
- ·Intracranial lesions or history of intracranial hypertension
- ·Scoliosis (monitor curve progression)
- ·Untreated hypothyroidism (treat before GH initiation)
- ·Severe obesity (assess OSA risk, cardiovascular status)
MOTS-c
- ·Active cancer or cancer predisposition
- ·AMPK pathway deficiency (efficacy nullified)
- ·Use with cancer-promoting medications (theoretical)
05Administration Protocol
Parameter
HGH 191AA
MOTS-c
1. Reconstitution (if lyophilized)
Add diluent (sterile water or bacteriostatic water per manufacturer) to vial. Swirl gently — do not shake. Solution should be clear, colorless. Concentration varies by brand (e.g., 5 mg or 10 mg per vial).
Add 1–2 mL bacteriostatic water. At 10 mg/vial, 1 mL gives 10 mg/mL concentration. Roll gently to dissolve.
2. Injection site
Subcutaneous — rotate sites: abdomen, thigh, buttocks, upper arm. Avoid same site within 1 cm for 2 weeks to prevent lipodystrophy.
Subcutaneous — abdomen, thigh, or deltoid. Rotate sites to avoid lipohypertrophy. Pinch fat layer.
3. Timing
Once daily, evening preferred (6–8 PM or pre-sleep). Mimics physiological nocturnal GH secretion. Consistency is critical.
Pre-workout or fasted state preferred — metabolic context amplifies AMPK response. 2–3× per week.
4. Storage
Unreconstituted: refrigerate 2–8 °C, protect from light. Reconstituted: refrigerate, use within 14–28 days (brand-specific). Do not freeze.
Lyophilised: room temp, protected from light. Reconstituted: refrigerate, use within 21–30 days. Short systemic stability.
5. Needle
27–31G, 4–8 mm insulin syringe or pen device. Pinch skin, 45–90° angle depending on subcutaneous thickness.
27–31G insulin syringe. Short needle (4–6 mm) for SQ delivery. Clean technique mandatory.
6. Monitoring
Baseline and periodic: IGF-1 (target age/sex-adjusted midrange), fasting glucose, HbA1c, thyroid function (TSH, free T4), bone age (children), lipid panel. Fundoscopy if headache/visual symptoms.
—
06Stack Synergy
HGH 191AA
+ Ipamorelin
ModerateIpamorelin (GHRP) stimulates endogenous GH release, which is redundant when exogenous rhGH is administered. However, ipamorelin may still amplify pulsatility of remaining endogenous secretion in partial GHD or during GH dose titration. Not typically combined in standard clinical practice; more common in experimental or off-label protocols. Limited evidence for additive benefit.
- HGH 191AA
- Standard dose per indication
- Ipamorelin
- 100–200 mcg SQ · morning (if used)
- Note
- Monitor IGF-1 closely; avoid supraphysiological levels
- Primary benefit
- Theoretical enhancement of pulsatility; limited clinical rationale
+ Tesamorelin
WeakTesamorelin (GHRH analogue) stimulates endogenous GH secretion, which is unnecessary when exogenous rhGH is already provided. Combining both offers no mechanistic advantage and increases cost, side effects, and IGF-1 elevation risk. Not recommended in clinical practice.
- Note
- Combination not recommended — choose one GH modality
- Primary benefit
- None — redundant mechanisms
MOTS-c
+ Ipamorelin
ModerateMOTS-c activates AMPK/PGC-1α for mitochondrial efficiency and fatty acid oxidation; ipamorelin stimulates GH for anabolic recovery and sleep depth. Pathways are complementary — MOTS-c handles metabolic flexibility and glucose handling while ipamorelin drives recovery and body recomposition through GH. Theoretical synergy is high; clinical data is lacking.
- MOTS-c
- 5 mg SQ · pre-workout (2–3×/wk)
- Ipamorelin
- 200–300 mcg SQ · pre-sleep (daily)
- Primary benefit
- Metabolic flexibility + GH recovery + ROS reduction